Monopar Therapeutics (NASDAQ:MNPR) CFO Purchases 1,500 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Quan Anh Vu acquired 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were bought at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the purchase, the chief financial officer owned 1,500 shares in the company, valued at $104,925. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Monopar Therapeutics Trading Down 1.6%

NASDAQ MNPR traded down $1.11 on Monday, reaching $67.66. 207,529 shares of the stock were exchanged, compared to its average volume of 71,179. Monopar Therapeutics Inc. has a one year low of $21.00 and a one year high of $105.00. The firm has a market capitalization of $451.95 million, a PE ratio of -19.69 and a beta of 1.46. The company’s 50-day simple moving average is $79.47 and its two-hundred day simple moving average is $60.26.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). Sell-side analysts forecast that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MNPR. Chardan Capital raised their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a report on Sunday, November 9th. Leerink Partners initiated coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th. Finally, Lake Street Capital assumed coverage on Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and a consensus target price of $106.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MNPR. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics in the third quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey bought a new position in Monopar Therapeutics during the second quarter valued at $34,000. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics in the 1st quarter worth $44,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after buying an additional 349 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.